Allegro Ophthalmics Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMD

– Intermediate Dry AMD Treatment Is a Significant Unmet Need – Mitochondrial Stabilizing Candidate Risuteganib Has Shown Best Corrected Visual Acuity Gains in Dry AMD Patient Population SAN JUAN CAPISTRANO, Calif., April 12, 2023 /PRNewswire/ — Allegro Ophthalmics, LLC, a privately held…